ID

29964

Descripción

Study of the Efficacy and Safety of Aliskiren HCTZ vs Ramipril in Obese Patients (BMI ≥ 30) With Stage 2 Hypertension; ODM derived from: https://clinicaltrials.gov/show/NCT00772577

Link

https://clinicaltrials.gov/show/NCT00772577

Palabras clave

Versiones (2)
  1. 30/4/18 30/4/18 -
  2. 30/4/18 30/4/18 -
Titular de derechos de autor

See clinicaltrials.gov

Subido en

30 de abril de 2018

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0
Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Volver a los comentarios del modelo
Comentarios de grupo de elementos para :

Comentarios del elemento para :

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Hypertension NCT00772577

Inglés

Eligibility Hypertension NCT00772577

1 formularios  
Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.
Descripción

Study Subject Participation Status eligible | Informed Consent

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C2348568
UMLS CUI [1,2]
C1548635
UMLS CUI [2]
C0021430
male or female outpatients, 18 years of age and older.
Descripción

Outpatients | Age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0029921
UMLS CUI [2]
C0001779
patients with stage 2 hypertension. patients must have a mssbp ≥ 160 mmhg and < 200 mmhg at study visit 5 (randomization).
Descripción

Hypertensive disease Stage | Sitting systolic blood pressure mean

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020538
UMLS CUI [1,2]
C0699749
UMLS CUI [2,1]
C1319893
UMLS CUI [2,2]
C0444504
patients must have a bmi ≥ 30 kg/m2 but ≤ 45 kg/m2.
Descripción

Body mass index

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1305855
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
office blood pressure measured by cuff (msdbp ≥ 110 mmhg and/or mssbp ≥ 200 mmhg) at any visit.
Descripción

Blood pressure determination | Sitting diastolic blood pressure mean | Sitting systolic blood pressure mean

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0005824
UMLS CUI [2,1]
C1319894
UMLS CUI [2,2]
C0444504
UMLS CUI [3,1]
C1319893
UMLS CUI [3,2]
C0444504
use of other investigational drugs within 30 days of enrollment, or 5 half-lives, which ever is longer.
Descripción

Investigational New Drugs

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0013230
use of aliskiren and/or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren and/or aliskiren hctz as treatment within 30 days of visit 1.
Descripción

Aliskiren | Hydrochlorothiazide | Combined Modality Therapy Dose Stable | Study Subject Participation Status

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1120110
UMLS CUI [2]
C0020261
UMLS CUI [3,1]
C0009429
UMLS CUI [3,2]
C0178602
UMLS CUI [3,3]
C0205360
UMLS CUI [4]
C2348568
history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (ace inhibitors or renin inhibitors) as the study drugs.
Descripción

Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Therapeutic class Same | Angiotensin-Converting Enzyme Inhibitors | Renin inhibitor

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0013230
UMLS CUI [2,1]
C0020517
UMLS CUI [2,2]
C0013227
UMLS CUI [2,3]
C3858838
UMLS CUI [2,4]
C0445247
UMLS CUI [3]
C0003015
UMLS CUI [4]
C1960108
history or evidence of a secondary form of hypertension.
Descripción

Secondary hypertension

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0155616
refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmhg). therapy with a fixed dose combination of two active substances represent two drugs.
Descripción

Refractory hypertension | Pharmacotherapy Triple Unresponsive to Treatment | Pharmaceutical Preparations Maximum Tolerated Dose | Diuretics | Blood Pressure Goal failed | Combined Modality Therapy | Pharmaceutical Preparations Quantity Dose Stable

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0860493
UMLS CUI [2,1]
C0013216
UMLS CUI [2,2]
C0205174
UMLS CUI [2,3]
C0205269
UMLS CUI [3,1]
C0013227
UMLS CUI [3,2]
C0752079
UMLS CUI [4]
C0012798
UMLS CUI [5,1]
C0005823
UMLS CUI [5,2]
C0679840
UMLS CUI [5,3]
C0231175
UMLS CUI [6]
C0009429
UMLS CUI [7,1]
C0013227
UMLS CUI [7,2]
C1265611
UMLS CUI [7,3]
C0178602
UMLS CUI [7,4]
C0205360
patients on 4 or more antihypertensive medications.
Descripción

Antihypertensive Agents Quantity

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0003364
UMLS CUI [1,2]
C1265611
long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening.
Descripción

Long QT Syndrome | QTc Duration | Gender

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023976
UMLS CUI [2,1]
C0860814
UMLS CUI [2,2]
C0449238
UMLS CUI [3]
C0079399
other protocol-defined inclusion/exclusion criteria may apply.
Descripción

Eligibility Criteria Study Protocol

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C1516637
UMLS CUI [1,2]
C2348563
Volver a la parte superior de la página

Similar models

Eligibility Hypertension NCT00772577

1 formularios
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
Study Subject Participation Status eligible | Informed Consent
Item
patients who are eligible and able to participate in the study, and who give written informed consent before any assessment is performed.
boolean
C2348568 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C0021430 (UMLS CUI [2])
Outpatients | Age
Item
male or female outpatients, 18 years of age and older.
boolean
C0029921 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
Hypertensive disease Stage | Sitting systolic blood pressure mean
Item
patients with stage 2 hypertension. patients must have a mssbp ≥ 160 mmhg and < 200 mmhg at study visit 5 (randomization).
boolean
C0020538 (UMLS CUI [1,1])
C0699749 (UMLS CUI [1,2])
C1319893 (UMLS CUI [2,1])
C0444504 (UMLS CUI [2,2])
Body mass index
Item
patients must have a bmi ≥ 30 kg/m2 but ≤ 45 kg/m2.
boolean
C1305855 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Blood pressure determination | Sitting diastolic blood pressure mean | Sitting systolic blood pressure mean
Item
office blood pressure measured by cuff (msdbp ≥ 110 mmhg and/or mssbp ≥ 200 mmhg) at any visit.
boolean
C0005824 (UMLS CUI [1])
C1319894 (UMLS CUI [2,1])
C0444504 (UMLS CUI [2,2])
C1319893 (UMLS CUI [3,1])
C0444504 (UMLS CUI [3,2])
Investigational New Drugs
Item
use of other investigational drugs within 30 days of enrollment, or 5 half-lives, which ever is longer.
boolean
C0013230 (UMLS CUI [1])
Aliskiren | Hydrochlorothiazide | Combined Modality Therapy Dose Stable | Study Subject Participation Status
Item
use of aliskiren and/or a fixed dose combination of aliskiren hctz or participation in a clinical trial that had aliskiren and/or aliskiren hctz as treatment within 30 days of visit 1.
boolean
C1120110 (UMLS CUI [1])
C0020261 (UMLS CUI [2])
C0009429 (UMLS CUI [3,1])
C0178602 (UMLS CUI [3,2])
C0205360 (UMLS CUI [3,3])
C2348568 (UMLS CUI [4])
Hypersensitivity Investigational New Drugs | Hypersensitivity Pharmaceutical Preparations Therapeutic class Same | Angiotensin-Converting Enzyme Inhibitors | Renin inhibitor
Item
history of hypersensitivity to any of the study drugs or to drugs belonging to the same therapeutic class (ace inhibitors or renin inhibitors) as the study drugs.
boolean
C0020517 (UMLS CUI [1,1])
C0013230 (UMLS CUI [1,2])
C0020517 (UMLS CUI [2,1])
C0013227 (UMLS CUI [2,2])
C3858838 (UMLS CUI [2,3])
C0445247 (UMLS CUI [2,4])
C0003015 (UMLS CUI [3])
C1960108 (UMLS CUI [4])
Secondary hypertension
Item
history or evidence of a secondary form of hypertension.
boolean
C0155616 (UMLS CUI [1])
Refractory hypertension | Pharmacotherapy Triple Unresponsive to Treatment | Pharmaceutical Preparations Maximum Tolerated Dose | Diuretics | Blood Pressure Goal failed | Combined Modality Therapy | Pharmaceutical Preparations Quantity Dose Stable
Item
refractory hypertension, defined as, unresponsive to triple drug therapy at the maximum dose of each drug, one of which must be a diuretic, and not at blood pressure goal (140/90 mmhg). therapy with a fixed dose combination of two active substances represent two drugs.
boolean
C0860493 (UMLS CUI [1])
C0013216 (UMLS CUI [2,1])
C0205174 (UMLS CUI [2,2])
C0205269 (UMLS CUI [2,3])
C0013227 (UMLS CUI [3,1])
C0752079 (UMLS CUI [3,2])
C0012798 (UMLS CUI [4])
C0005823 (UMLS CUI [5,1])
C0679840 (UMLS CUI [5,2])
C0231175 (UMLS CUI [5,3])
C0009429 (UMLS CUI [6])
C0013227 (UMLS CUI [7,1])
C1265611 (UMLS CUI [7,2])
C0178602 (UMLS CUI [7,3])
C0205360 (UMLS CUI [7,4])
Antihypertensive Agents Quantity
Item
patients on 4 or more antihypertensive medications.
boolean
C0003364 (UMLS CUI [1,1])
C1265611 (UMLS CUI [1,2])
Long QT Syndrome | QTc Duration | Gender
Item
long qt syndrome or qtc > 450 msec for males and > 470 msec for females at screening.
boolean
C0023976 (UMLS CUI [1])
C0860814 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0079399 (UMLS CUI [3])
Eligibility Criteria Study Protocol
Item
other protocol-defined inclusion/exclusion criteria may apply.
boolean
C1516637 (UMLS CUI [1,1])
C2348563 (UMLS CUI [1,2])
Volver a la parte superior de la página 

Contacto

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Ayuda

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial